Post-acute sequelae of COVID-19 in people of Black ethnicities living with HIV in the United Kingdom

Abstract

Background

The COVID-19 pandemic disproportionately affected people of Black ethnicities, however, there are limited data on the post-acute sequelae of COVID-19 infection in these populations, and none in those with HIV.

Methods

We conducted a cross-sectional study in people of Black ethnicities with HIV in the UK. Participants were assessed for functional impairment, frailty, respiratory symptoms, anxiety and depression; they were also asked to rate aspects of their physical and mental health on a scale from 1 (poor) to 10 (excellent), both at enrolment and prior to the pandemic. We report associations with COVID-19 history and recovery status.

Results

We enrolled 183 participants between June 2021 and October 2022, 131 (72%) of whom reported COVID-19. A history of COVID-19 was associated with a reduced ability to carry out usual activities (OR 2.54 [1.03–6.21], p = 0.04), an increase in pain, tiredness and breathlessness, and overall decline in physical health. Of those with a history of COVID-19, 111 (85%) reported to have fully recovered. Those who had not fully recovered reported poorer functional status (p < 0.001) and had higher generalised anxiety scores (p = 0.02). Objective measures of physical function were similar in those who reported no COVID-19, COVID-19 with full recovery, and COVID-19 with incomplete recovery.

Conclusions

In this cohort of Black people with HIV, participants with a history of COVID-19 reported a reduced ability to carry out activities of daily living and various other health issues. Although most people reported full recovery from COVID-19, self-reported limitations in functional status and anxiety were common sequelae.

Keywords

Black HIV COVID-19 long-COVID

Introduction

The post-acute sequelae of COVID-19 include physical, neurocognitive, and mental health impairments such as respiratory symptoms, pain, fatigue, sleep disturbance, depression and anxiety.^1,2 Collectively, these multisystem sequelae are also known as long-COVID.³ Large cohort studies have reported up to 1 in 5 adults develop long-COVID,^4–6 predominantly following an initial SARS-CoV-2 infection (as compared to reinfection).⁷ Long-COVID constitutes a significant public health burden, thought to affect at least 65 million individuals around the world^8,9 and around 3% of the UK population.¹⁰

Research into the pathogenesis and treatment of long-COVID is ongoing¹¹ including large clinical research studies such as the National Institutes of Health and Care Research “Researching COVID to Enhance Recovery (RECOVER)” program¹² in the general UK population. Pre-existing comorbidities have been linked to an increased risk of long-COVID including obesity,^13–15 cardiovascular disease,^4,14 kidney disease,¹⁴ chronic lung disease,¹⁵ diabetes,¹⁶ depression and anxiety^15,16 and dementia.¹⁴ In addition to comorbidities, inflammatory markers, such as C-Reactive Protein (CRP), have also been shown to be persistently elevated in those with long-COVID and persist for up to 7 months post- acute infection.¹⁷

The COVID-19 pandemic is known to have disproportionately affected people of Black ethnicities, with higher rates of COVID-19 acquisition, morbidity and mortality.^18–20 Several studies have explored ethnic disparities in long-COVID.^21–25 Results are mixed, with some studies demonstrating an increased prevalence of symptoms amongst people of Black ethnicity,^21,23–26 and others failing to show an association.^15,22 Research on long-COVID in these populations is needed to better understand the consequences of the pandemic in those who were most affected by it.²⁷

People living with HIV with poor immunovirological control are at increased risk of adverse COVID-19 outcomes.^28–33 A global meta-analysis of 17 studies revealed that an estimated 52% of people living with HIV who reported a SARS-CoV-2 illness developed at least one long-COVID symptom.³⁴ Whilst previous studies have evaluated the impact of ethnicity or HIV status on long-COVID, to our knowledge, there are no studies which have explored the long-term sequelae of COVID-19 in people of Black ethnicities living with HIV. In the present study, we report on the long-term sequelae of COVID-19 in this population.

Methods

During routine HIV clinic visits between June 2021 and October 2022, people of Black ethnicities who had previously participated in the Genetic Determinants of Kidney Disease in People of African Ancestry with HIV (GEN-AFRICA) study (NCT05685810) were invited to take part in the COVID-AFRICA parent study (IRAS 294887), and a subset of these in the cross-sectional COVID-19 sequelae study. Enrolment into the COVID-19 sequelae was open to individuals irrespective of their COVID-19 history, however, we aimed for at least half of participants to have experienced COVID-19, and this data was gathered at the COVID-AFRICA parent study visit..

The study was approved by a National Health Service Research Ethics Committee (21/PR/0529) and the Health Research Authority (IRAS 295943). All participants provided written informed consent and received £10 cash for their time and effort.

Participants completed questionnaires evaluating their physical and mental health, functional status and well-being. They were asked to rate their current physical health, sleep, tiredness, pain, mobility, ability to independently self-care and carry out usual activities, memory, concentration and wellbeing on a 10-point scale ranging from 1 (poor) to 10 (excellent); they were additionally asked to rate these same factors just before the pandemic, to report current respiratory symptoms (cough, breathlessness, phlegm), and to complete assessments of their mental health (Patient Health Questionnaire-9³⁵ and Generalised Anxiety Disorder-7 score³⁶). Participants who had experienced COVID-19 were asked whether they had fully recovered or not.

We assessed physical status using the Clinical Frailty Score,³⁷ functional status,³⁸ and by measuring heart rate, respiratory rate, and oxygen saturations (breathing room air) at rest and after the one-minute sit-to-stand test,³⁹ and the 4-m gait speed.⁴⁰ Blood samples were obtained to measure CRP.

Statistical analyses

We described the characteristics of the study population, overall and stratified by COVID-19 (recovery) status, with comparisons using Pearson’s χ² test (or exact tests where expected numbers were small) for categorical variables and Kruskal-Wallis test or analysis of variance for continuous variables, as appropriate.

We determined the proportions of participants who rated aspects of their physical and mental health lower at the time of enrolment, as compared to pre-pandemic. A ≥1 point decline was considered to be ‘any’ decline and a ≥2 point decline was considered to be a moderate-severe decline. Odds ratios (adjusted for age and sex) of the association of COVID-19 status with each outcome were calculated using logistic regression analysis.

We also compared physical status, respiratory symptoms and mental health, overall and stratified by COVID-19 and recovery status, using Pearson’s χ² test/exact tests and Kruskal-Wallis tests, as above.

All analyses were performed using STATA v17 (StataCorp, College Station, TX). p values < 0.05 were considered significant.

Results

A total of 183 people were enrolled in the COVID-19 sequelae study, 131 (72%) of whom reported a history of COVID-19. The demographic and clinical characteristics of the participants, stratified by COVID-19 status, are shown in Table 1. Participants had a median age of 52 [interquartile range: IQR 45–59] years, 56% were female, and most (79%) were of sub-Saharan African ancestry, with long-standing (median 15 years) and well controlled HIV (median CD4 cell count 575 cells/mm³, 89% HIV RNA <200 copies/mL). We found no evidence that specific antiretrovirals were associated with COVID-19. Hypertension, obesity and diabetes were present in 57%, 47% and 18% of participants, respectively, and 6%–10% had cardiovascular, kidney and lung disease. Participants who had developed COVID-19 were younger and more often female (Table 1); the median time between COVID-19 illness and the study visit was 311 (IQR 142-581) days, 13 (10%) reported to have been hospitalised for COVID-19, and 111 (85%) to have fully recovered. A total of 170 (93%) had received at least one dose of SARS-CoV-2 vaccine.

Table 1.

Demographic and clinical characteristics of the study participants stratified by COVID-19 status.

Pre-pandemic participant characteristics		TotalN = 183	No COVID-19N = 52	COVID-19N = 131	p value
Demographic parameters
Age, years	Median (IQR)	52 (45–59)	56 (48–59)	52 (45–58)	0.03
Sex, female	N (%)	103 (56.3)	23 (44.2)	80 (61.1)	0.04
Region of ancestry	N (%)				0.23
Sub-Saharan Africa		145 (79.2)	38 (73.1)	107 (81.7)
Caribbean		29 (15.9)	12 (23.1)	17 (13.0)
Other/unknown		9 (4.9)	2 (3.9)	7 (5.3)
HIV parameters
Time since HIV diagnosis, years	Median (IQR)	15 (9–18)	14 (7–17)	15 (11–18)	0.17
Nadir CD4 cell count, cells/mm³	Median (IQR)	250 (104–386)	228 (111–378)	253 (104–390)	0.95
Recent CD4 cell count, cells/mm³	Median (IQR)	575 (428–787)	537 (336–775)	586 (448–798)	0.33
HIV RNA <200 copies/mL	N (%)	161 (88.5)	47 (90.4)	114 (87.7)	0.60
Antiretroviral NRTI	N (%)				0.50
Tenofovir disoproxil fumarate		55 (36.2)	14 (30.4)	41 (38.7)
Tenofovir alafenamide		44 (29.0)	16 (34.8)	28 (26.4)
Abacavir		53 (34.9)	16 (34.8)	37 (34.9)
Antiretroviral third agent	N (%)				0.07
NNRTI		62 (34.6)	12 (23.1)	50 (39.4)
INSTI		78 (43.6)	29 (55.8)	49 (38.6)
PI		39 (21.8)	11 (21.2)	28 (22.1)
Comorbid status
Current smoker	N (%)	15 (8.2)	8 (15.4)	7 (5.3)	0.03
Obesity^a	N (%)	86 (47.3)	22 (42.3)	64 (49.2)	0.40
Hypertension	N (%)	104 (57.1)	35 (67.3)	69 (53.1)	0.08
Diabetes	N (%)	33 (18.0)	12 (23.1)	21 (16.0)	0.26
Cardiovascular disease^b	N (%)	19 (10.4)	6 (11.5)	13 (9.9)	0.75
Kidney disease^c	N (%)	19 (10.4)	5 (9.6)	14 (10.7)	0.83
Lung disease^d	N (%)	10 (6.3)	1 (1.9)	9 (6.9)	0.18

^aObesity = body mass index ≥30 kg/m².

^bCardiovascular disease = myocardial infarction, coronary artery disease, peripheral vascular disease, stroke, heart failure, and/or cardiomyopathy.

^cKidney disease = estimated glomerular filtration rate <60 mL/min/1.73 m².

^dLung disease = asthma, chronic obstructive pulmonary disease, interstitial lung disease.

IQR, interquartile range; NRTI, nucleoside reverse-transcriptase inhibitor; NNRTI, non-nucleoside reverse-transcriptase inhibitor; INSTI, integrase strand-transfer inhibitor; PI, protease inhibitor.

Table 2 shows the proportion of participants who rated their physical health, sleep, tiredness, pain, mobility, ability to independently self-care and carry out usual activities, memory, concentration and wellbeing (at least 1 and at least 2 points on a 10-point scale) worse than prior to the pandemic. A greater proportion of those with a history of COVID-19 rated their physical and mental health (except for self-care) worse at the time of enrolment (verses pre-pandemic), as compared to those who had remained free of COVID-19. When adjusted for age and sex, those with a history of COVID-19 (as compared to those without) were significantly more likely to report a reduced ability to carry out usual activities of daily living (OR 2.54 [1.03–6.21], p = 0.04) at the study visit compared to pre-pandemic. Similar results were obtained for a moderate-severe decline in the ability to carry out usual activities (OR 3.54 [1.00–12.50], p = 0.05) (Table 2). There were also associations (although of borderline statistical significance) between a history of COVID-19 and a decline in several other aspects of physical and mental health; notably increased pain (OR 2.18 [0.96–4.95], p = 0.06), lower overall physical health (OR 2.06 [0.97–4.38], p = 0.06), and increased tiredness (OR 2.03 [0.96–4.31], p = 0.07). Similar associations were also generally observed for moderate-severe decline in these health parameters (Table 2).

Table 2.

Changes in physical and mental health assessments, stratified by COVID-19 status and adjusted for age and sex^a.

Physical and mental health parameters		Self-reported ratings of physical and mental health pre-pandemic to now
		Any decline (vs. no decline)					Moderate-severe decline (vs. no-mild decline)
		AllN = 183^b	No COVIDN = 52	COVIDN = 131	OR(95% CI)	p value	AllN = 183^b	No COVIDN = 52	COVIDN = 131	OR(95% CI)	p value
Usual activities	N (%)	46 (25.2)	7 (13.5)	39 (29.8)	2.54 (1.03–6.21)	0.04	27 (14.8)	3 (5.8)	24 (18.3)	3.54 (1.00–12.50)	0.05
Pain		53 (29.0)	9 (17.3)	44 (33.6)	2.18 (0.96–4.95)	0.06	41 (22.4)	8 (15.4)	33 (25.2)	1.68 (0.71–4.01)	0.24
Physical health		67 (36.6)	12 (23.1)	55 (42.0)	2.06 (0.97–4.38)	0.06	41 (22.4)	7 (13.5)	34 (26.0)	1.75 (0.70–4.40)	0.23
Tiredness		64 (35.0)	12 (23.1)	52 (39.7)	2.03 (0.96–4.31)	0.07	51 (27.9)	9 (17.3)	42 (32.1)	2.15 (0.94–4.93)	0.07
Sleep		57 (31.2)	11 (21.2)	46 (35.1)	1.71 (0.78–3.74)	0.18	45 (24.6)	9 (17.3)	36 (27.5)	1.56 (0.67–3.60)	0.30
Memory		53 (29.0)	11 (21.2)	42 (32.1)	1.61 (0.74–3.52)	0.23	26 (14.2)	5 (9.6)	21 (16.0)	1.54 (0.53–4.49)	0.43
Mobility		56 (30.6)	13 (25.0)	43 (32.8)	1.42 (0.68–2.99)	0.35	36 (19.7)	6 (11.5)	30 (22.9)	2.06 (0.79–5.38)	0.14
Concentration		52 (28.4)	12 (23.1)	40 (30.5)	1.31 (0.61–2.82)	0.49	34 (18.6)	9 (17.3)	25 (19.1)	1.13 (0.47–2.71)	0.78
Wellbeing		60 (32.8)	14 (26.9)	46 (35.1)	1.30 (0.62–2.71)	0.48	41 (22.4)	8 (15.4)	33 (25.2)	1.76 (0.74–4.20)	0.20
Self-care		17 (9.3)	5 (9.6)	12 (9.2)	0.91 (0.29–2.80)	0.87	10 (5.5)	4 (7.7)	6 (4.6)	0.61 (0.16–2.35)	0.48

^aData are shown as N (%), with corresponding Odds Ratios (95% confidence intervals) adjusted for age and sex, and p values, for participants who rated their physical and/or mental health lower (on a scale of 1 ‘poor’ to 10 ‘excellent’) at the time of study enrolment, as compared to their rating pre-pandemic, by ≥1 point (any decline) or ≥2 point (moderate-severe decline).

^bData for 180–183 participants.

OR, odds ratio; CI, confidence interval.

We describe several additional assessments in participants stratified by their COVID-19 status (no COVID-19 and COVID-19) in Table 3. The two groups differed in terms of clinical frailty score; those with no COVID-19 history were more likely to report that they were ‘very fit’, whereas those who had a history of COVID-19 were more likely to report that they were ‘fit’. Additionally, those with a history of COVID-19 were also more likely to report breathlessness that was worse compared to prior to the pandemic.

Table 3.

Physical status, respiratory symptoms and mental health, stratified by COVID-19 status.

Participants physical status, respiratory symptoms and mental health		TotalN = 183	No COVID-19N = 52	COVID-19N = 131	p value
Time from COVID-19 to study visit (days)	Median (IQR)	N/A	N/A	311 (142–581)	N/A
Functional status grade	N (%)				0.69
No limitations		95 (62.9)	30 (65.2)	65 (61.9)
Negligible limitations		18 (11.9)	4 (8.7)	14 (13.3)
Slight limitations		20 (13.3)	7 (15.2)	13 (12.4)
Moderate limitations		8 (5.3)	1 (2.2)	7 (6.7)
Severe limitations		10 (6.6)	4 (8.7)	6 (5.7)
Clinical frailty score	N (%)				0.04
Very fit		39 (22.7)	15 (30.0)	24 (19.7)
Fit		62 (36.1)	10 (20.0)	52 (42.6)
Managing well		50 (29.1)	17 (34.0)	33 (27.1)
Living with frailty		21 (12.2)	8 (16.0)	13 (10.7)
Shortness of breath	N (%)				0.49
No breathlessness		70 (40.7)	23 (46.9)	47 (38.2)
Breathless uphill		73 (42.4)	17 (34.7)	56 (45.5)
Breathless when walking slower than people of same age, stop when walking		9 (5.2)	4 (8.2)	5 (4.1)
Breathless and need to stop after 100 m or a few minutes		17 (9.9)	4 (8.2)	13 (10.6)
Breathless when dressing, unable to leave house		3 (1.7)	1 (2.0)	2 (1.6)
Breathless worse than pre-pandemic	N (%)	29 (28.4)	2 (7.7)	27 (35.5)	0.007
Cough	N (%)				0.11
No cough		108 (61.7)	36 (73.5)	72 (57.1)
Cough a few days a month		47 (26.9)	8 (16.3)	39 (31.0)
Cough several or most days of the week		20 (11.4)	5 (10.2)	15 (11.9)
Cough worse than pre-pandemic	N (%)	23 (36.5)	4 (30.8)	19 (38.0)	0.63
Phlegm (if cough)	N (%)	24 (36.4)	4 (8.2)	20 (37.7)	0.64
Mental health assessments
GAD score	Mean (SD)	6.0 (6.5)	5.1 (5.6)	6.0 (6.5)	0.64
PHQ-9 score	Mean (SD)	14.7 (6.6)	15.5 (6.4)	14.7 (6.6)	0.34

IQR, interquartile range; SD, standard deviation.

We also compared the characteristics and assessments for those who had, and those who had not, fully recovered from COVID-19. These two groups had similar demographic and clinical characteristics including age, nadir and current CD4 cell counts and proportions with suppressed HIV RNA (Table S1). Those who reported not to have fully recovered from COVID-19 had developed COVID-19 more recently (median 145 vs 354 days, p = 0.005) and were more likely to report that they were living with slight or moderate limitations in their functional status and frailty; they also had significantly higher anxiety scores, and this result was statistically significant (Table S2). An analysis restricted to participants who had experienced and fully recovered from COVID-19 in the preceding 12 months showed broadly similar results (Table S3).

Finally, there were no significant differences in effort tolerance, gait speed, respiratory rates, heart rates, and oxygen saturations (at rest or at the end of the one-minute sit-to-stand test), or in CRP levels among those not recovered from COVID-19, those who had recovered, and those without COVID-19 (Table S4).

Discussion

Our study evaluated sequelae of COVID-19 in a cohort of people of Black ethnicities living with HIV in UK. Even though 85% of participants reported full recovery from COVID-19 and most had well-controlled HIV, a history of COVID-19 was associated with a reduced ability to carry out activities of daily living, increased pain, tiredness and breathlessness, and overall decline in physical health. Our results suggest there may be a substantial burden of long-COVID in people of Black ethnicities with HIV.

Studies in the general population have similarly reported an association between COVID-19 and a reduced ability to carry out daily activities,¹⁰ an increase in pain^10,41 and a worsening of tiredness or fatigue.^1,24,41,42 These studies^43–45 also reported impairments of sleep, memory, mobility, wellbeing and concentration in participants who had COVID-19, but (as in our study) these associations did not achieve statistical significance. By contrast, the ability to self-care in our participants was unaffected by COVID-19, and the shorter time between the COVID-19 illness and the assessments in those not having fully recovered is in line with reports of a decline in the prevalence of long-COVID over time.⁴⁶

Approximately one third of participants with a history of COVID-19 reported breathlessness that was worse compared to prior to the pandemic. However, current levels of shortness of breath, and physical cardiorespiratory assessments at rest and post-exercise, were similar for those with and without COVID-19. Previous research of severe acute respiratory syndrome showed pulmonary changes on computed tomography reported up to 7 years after infection.⁴⁷ Other studies in the general population have also found breathlessness scales were above pre-COVID baselines in those with long-COVID^1,10 with some studies focused on ethnic minorities, suggesting people of Black ethnicities with long-COVID may be more likely to experience dyspnoea as compared to other ethnic groups.^24,25 Unfortunately, our study does not have objective, pre-pandemic assessment of cardio-respiratory function for comparison or radiological studies to evaluate for persistent lung parenchymal abnormalities.

Our results showing that incomplete recovery from COVID-19 was characterized by general functional impairments and (generally mild) frailty are consistent with previous reports.^48,49 Our results are also in keeping with previous studies from the general population which show an increased rate of generalised anxiety disorder amongst those with long-COVID.^1,48 One case-control study identified signs of neuroinflammation using CT-PET in individuals post COVID-19 and found those with motor slowing and persistent neuropsychiatric symptoms had higher translocator protein distribution volume (an index of gliosis and inflammatory change).⁵⁰ A metanalysis among people living with HIV reported the most common long-COVID symptoms to be neurological rather than respiratory.³⁴

Qualitative studies have previously explored the lived experiences of the COVID-19 pandemic,⁵¹ including long-COVID,^52,53 amongst Black populations with HIV and highlighted the worsening health and social inequalities due to the pandemic. Data show people of mixed ethnicity and those born outside the UK are less likely to be referred to long-COVID services, despite being more prone to experiencing symptoms.^16,54 This highlights the need to ensure equitable access to long-COVID services, and targeted strategies to improve long-COVID outcomes amongst disadvantaged communities who may experience help-seeking barriers.^53,55

The strengths of our study include the ethnic diversity of the Black study participants and the inclusion of all COVID-19 cases, regardless of severity. Our study is limited by its cross-sectional design, lack of follow-up visits and lack of young participants. It was designed and conducted before a consensus long-COVID definition, long-COVID subtypes and a validated symptom burden questionnaire were developed.^42,56–58 Many of our outcomes were self-reported and subjective. Awareness of COVID-19 status may have impacted willingness to participate, influenced reported mental and physical health ratings, and the use of retrospective recall in the case of pre-pandemic health is duly acknowledged as a limitation. We sought to overcome this potential source of bias through the use of suitable response sets in the questionnaire (e.g., “ Did you feel affected by tiredness BEFORE the pandemic?”), as per recommendations for health-related COVID–19 research.⁵⁹

The changes in symptomology with different SARS-CoV-2 variants, following vaccination, and as the pandemic progressed are well documented anecdotally and in studies.⁶⁰ It is important to note our study was performed in 2021/22, when a significant number of people were admitted to hospital with severe lung infection secondary to SARS-CoV-2 (10% in this cohort). As a result, the long-COVID symptoms documented in our study may differ from symptom profiles reported in more recent years.⁶⁰ The modest sample size, resulting in limited power to detect statistical differences for some of the comparisons, along with no power analyses and the multiple outcomes examined, led us to focus on effect sizes (and consistency of these) rather than statistical significance per se.

In summary, in this study of people of Black ethnicities living with HIV in the UK, a history of COVID-19 was associated with a decline in physical and mental wellbeing. About 15% of those with COVID reported incomplete recovery and these individuals reported functional limitations, a degree of frailty, breathlessness and anxiety. Given our limitations, future studies with large sample sizes are needed to explore the pathophysiological mechanisms of long-COVID; such studies should include representation of ethnic minorities including those living with HIV to ensure equitable post-COVID healthcare for the most severely affected populations.

Supplemental Material

Supplemental Material - Post-acute sequelae of COVID-19 in people of Black ethnicities living with HIV in the United Kingdom

Supplemental Material - Post-acute sequelae of COVID-19 in people of Black ethnicities living with HIV in the United Kingdom by Zoe Ottaway, Lucy Campbell, Julie Fox, Fiona M. Burns, Lisa Hamzah, Sarah Schoeman, David Price, Amanda Clarke, Sarah L. Pett, Denis Onyango, Caroline Sabin, Robert F. Miller, Frank A. Post and on behalf of the COVID-AFRICA study group.

Footnotes

Acknowledgements

The authors would like to thank the study participants, participating sites and all members of the COVID-AFRICA study group ().

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The COVID-AFRICA study was funded through a grant from Gilead Sciences (IN-UK-983-6053).

Ethical statement

ORCID iDs

Zoe Ottaway

Robert F. Miller

Frank A. Post

Data Availability Statement

The database contains personal and sensitive information and is therefore not publicly available. Access to the study data and/or samples is governed by the National Health Service data access policy and those of King’s College Hospital NHS Foundation Trust, the study sponsor. The Gen-AFRICA and COVID-AFRICA studies are open to collaborations, and all requests from researchers who meet the criteria for access to fully anonymized patient level data will be considered. Concepts can be submitted for review to the principal investigator (Prof. Frank Post; email: frank.post@kcl.ac.uk).

Supplemental Material

Supplemental material for this article is available online.

Appendix

COVID-AFRICA group: Study sites and staff

University Hospitals Sussex NHS Foundation Trust, University Hospitals Sussex NHS Foundation Trust, Brighton (Amanda Clarke [PI], Marion Campbell, Alyson Knott, Lisa Barbour, Vittorio Trevitt).

Chelsea and Westminster NHS, Chelsea and Westminster NHS Foundation Trust, London (Rachael Jones [PI], Alex Schoolmeesters, Shoreh Ghazali).

Guys and St Thomas’s NHS Foundation Trust, London (Julie Fox [PI], Anele Waters, Mariusz Racz, Louise Terry, Kathy Arbis).

King’s College Hospital NHS Foundation TrustLondon (Frank Post et al., King’s College Hospital NHS Foundation Trust, London (Frank Post [CI], Zoe Ottaway, Beatriz Santana-Suarez, Leigh McQueen, Lucy Campbell, Bee Barbini, Emily Wandolo, Rachel Hung, Luella Hanbury, Sarah Barber, Chris Taylor, Mary Poulton, Holly Middleditch, Itty Samuel, Candice McDonald, Vladimir Kolodin, Laura Cechin, Larissa Mulka, Amy John, Sally Hawkins, Madelaine Angus, Tim Appleby, Katherine Bainbridge, Hayley Cheetham, Julie Barker, Kate Childs, Rousell Roberts, Nivenjit Kaur, Lisa Shorrock, Kate El Bouzidi, Nisha Patel, Amelia Oliveira, Ayoma Ratnappuli, Kate Flanagan, Daniel Trotman, Nisha Mody, Michael Brady, Killian Quinn, Elizabeth Hamlyn, Gurjinder Sandhu, Verity Sullivan, Naomi Fitzgerald).

Leeds Teaching Hospitals NHS Trust, Leeds (Sarah Schoeman [PI], Gary Lamont, Natasha Calder-Smith, Tadas Mazeika, Kiran Chana).

North Manchester General Hospital, Manchester (Andrew Ustianowski [PI], Gabriella Lindergard, Jan Flaherty, Valerie George, Denise Kadiu, Alice Hendy, Kevin Kuriakose).

Mortimer Market Centre, Mortimer Market Centre; Central and North West London NHS Foundation Trust, London (Sarah Pett [PI], Mah Jabeen Qamar, Jose Paredes Sosa, Konstantina Tetorou, Michelle Beynon, Adesola Yinka-Ogunleye, Gosala Gopalakrishnan, Irfaan Maan, Claire Mullender).

Newcastle Hospitals NHS Foundation Trust et al., Newcastle Hospitals NHS Foundation Trust, Newcastle (David Ashley Price [PI], Bijal Patel, Ian McVittie).

Queen Elizabeth Hospital and Lewis, Queen Elizabeth Hospital, Woolwich; Lewisham and Greenwich NHS Trust, London (Stephen Kegg [PI], Chloe Saad, Rosa Harrington, Kirsty Cunningham, Mandy Lewis).

Royal Free London NHS Foundation TrustLondon (Fiona Burns et al., Royal Free London NHS Foundation Trust, London (Fiona Burns [PI], Jonathan Edwards, Tom Fernandez, Katie Spears).

St George’s University Hospital NHS Foundation Trust, London (Lisa Hamzah [PI], Catherine Cosgrove, Hannah Laurence, Ameen Rahman, Katie Toler).

University Hospital Lewisham, University Hospital Lewisham; Lewisham and Greenwich NHS Trust, London (Melanie Rosenvinge [PI], Claudia Adade, Shelley Campbell).

Africa Advocacy Foundation (Denis Onyango).

References

D’Cruz

Waller

Perrin

, et al. Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia. ERJ Open Res 2021; 7(7): 655–2020. DOI: 10.1183/23120541.00655-2020.

Peter

Nieters

Kräusslich

, et al. Post-acute sequelae of COVID-19 six to 12 months after infection: population based study. BMJ 2022: 379. https://pubmed.ncbi.nlm.nih.gov/36229057/

Parotto

Gyöngyösi

Howe

, et al. Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations. Lancet Respir Med 2023; 11(8): 739–754. https://www.thelancet.com/article/S2213260023002394/fulltext

Oelsner

Sun

Balte

, et al. Epidemiologic features of recovery from SARS-CoV-2 infection. JAMA Netw Open 2024; 7(6): e2417440. https://pubmed.ncbi.nlm.nih.gov/38884994/

Fitzpatrick

Cope

, et al. Estimates of incidence and predictors of fatiguing illness after SARS-CoV-2 infection. Emerg Infect Dis 2024; 30(3): 539–547. https://pubmed.ncbi.nlm.nih.gov/38407166/

Rischard

Altman

Szmuszkovicz

, et al. Long-term effects of COVID-19 on the cardiopulmonary system in adults and children: current status and questions to be resolved by the National Institutes of Health researching COVID to enhance recovery initiative. Chest 2024; 165(4): 978–989. https://pubmed.ncbi.nlm.nih.gov/38185377/

Hadley

Yoo

Patel

, et al. Insights from an N3C RECOVER EHR-based cohort study characterizing SARS-CoV-2 reinfections and Long COVID. Commun Med 2024; 4(1): 129. https://pubmed.ncbi.nlm.nih.gov/38992084/

Davis

McCorkell

Vogel

, et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023; 21(3): 133–146. https://www.nature.com/articles/s41579-022-00846-2

Lancet

. Long COVID: 3 years in. Lancet 2023; 401(10379): 795. https://www.thelancet.com/article/S0140673623004932/fulltext

10.

Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK - office for National Statistics, 2024. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/2february2023#prevalence-of-ongoing-symptoms-following-coronavirus-infection-in-the-uk-data

11.

Elliott

O’Connor

Marshall

. Inflammatory pathways in patients with post-acute sequelae of COVID-19: the role of the clinical immunologist. Ann Allergy Asthma Immunol 2024; 133(5): 507–515.

12.

RECOVER clinical trials | home, 2024. https://trials.recovercovid.org/

13.

Zhou

Zhang

, et al. Body mass index and postacute sequelae of SARS-CoV-2 infection in children and young adults. JAMA Netw Open 2024; 7(10): e2441970. https://pmc.ncbi.nlm.nih.gov/articles/PMC11581483/

14.

Zang

Hou

Schenck

, et al. Identification of risk factors of Long COVID and predictive modeling in the RECOVER EHR cohorts. Commun Med 2024; 4(1): 130. https://pubmed.ncbi.nlm.nih.gov/38992068/

15.

Hill

Mehta

Sharma

, et al. Risk factors associated with post-acute sequelae of SARS-CoV-2: an N3C and NIH RECOVER study. BMC Public Health 2023; 23(1): 2103. https://pubmed.ncbi.nlm.nih.gov/37880596/

16.

Wang

Doran

Crooks

, et al. Prevalence, risk factors and characterisation of individuals with long COVID using Electronic Health Records in over 1.5 million COVID cases in England. J Infect 2024; 89(4): 106235. https://pubmed.ncbi.nlm.nih.gov/39121972/

17.

Espín

Yang

Shannon

, et al. Cellular and molecular biomarkers of long COVID: a scoping review. EBioMedicine 2023. https://www.thelancet.com/article/S2352396423001172/fulltext

18.

Sze

Pan

Nevill

, et al. Ethnicity and clinical outcomes in COVID-19: a systematic review and meta-analysis. EClinicalMedicine 2020; 29(100630).

19.

Pareek

Bangash

Pareek

, et al. Ethnicity and COVID-19: an urgent public health research priority. Lancet 2020; 395(10234): 1421–1422.

20.

Apea

Wan

Dhairyawan

, et al. Original research: ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: an observational cohort study. BMJ Open 2021; 11(1): 42140.

21.

Khullar

Zhang

Zang

, et al. Racial/ethnic disparities in post-acute sequelae of SARS-CoV-2 infection in New York: an EHR-based cohort study from the RECOVER program. J Gen Intern Med 2023; 38(5): 1127–1136. https://pubmed.ncbi.nlm.nih.gov/36795327/

22.

Naidu

Saigal

Shah

, et al. Associations between ethnicity and persistent physical and mental health symptoms experienced as part of ongoing symptomatic COVID-19. PLoS One 2024; 19(10): e0312719. https://pubmed.ncbi.nlm.nih.gov/39480857/

23.

Jacobs

Evans

Ellis

. Racial, ethnic, and sex disparities in the incidence and cognitive symptomology of long COVID-19. J Natl Med Assoc 2023; 115(2): 233–243. https://pmc.ncbi.nlm.nih.gov/articles/PMC9923441/

24.

Yomogida

Zhu

Rubino

, et al. Post-acute sequelae of SARS-CoV-2 infection among adults aged ≥18 Years - Long Beach, California, April 1-December 10, 2020. MMWR Morb Mortal Wkly Rep 2021; 70(37): 1274–1277. https://pubmed.ncbi.nlm.nih.gov/34529639/

25.

Halpin

McIvor

Whyatt

, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol 2021; 93(2): 1013–1022. https://pubmed.ncbi.nlm.nih.gov/32729939/

26.

Wang

Jonas

. The likelihood of severe COVID-19 outcomes among PLHIV with various comorbidities: a comparative frequentist and Bayesian meta-analysis approach. J Int AIDS Soc 2021; 24(11): e25841. https://pubmed.ncbi.nlm.nih.gov/34797952/

27.

Norredam

Hayward

Deal

, et al. Understanding and addressing long-COVID among migrants and ethnic minorities in Europe. Lancet Reg Health Eur 2022: 19. https://pubmed.ncbi.nlm.nih.gov/35789882/

28.

Nomah

Reyes-Urueña

Díaz

, et al. Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. Lancet HIV 2021; 8(11): e701–e710.

29.

Wit

Reiss

Rijnders

, et al. COVID-19 in people with HIV in The Netherlands. AIDS 2023; 37(11): 1671–1681. https://pubmed.ncbi.nlm.nih.gov/37199566/

30.

Childs

Post

Norcross

, et al. Hospitalized patients with COVID-19 and human immunodeficiency virus: a case series. Clin Infect Dis 2020; 71(8): 2021–2022.

31.

Shapiro

Bender Ignacio

Whitney

, et al. Factors associated with severity of COVID-19 disease in a multicenter cohort of people with HIV in the United States, March-December 2020. J Acquir Immune Defic Syndr 1988; 90(4): 369–376.

32.

Jassat

Cohen

Tempia

, et al. Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study. Lancet HIV 2021; 8(9): e554–e567.

33.

Ottaway

Campbell

Cechin

, et al. Clinical epidemiology of COVID-19 in people of Black ethnicity living with HIV in the UK. HIV Med 2024. https://onlinelibrary.wiley.com/doi/full/10.1111/hiv.13611

34.

Yang

Shi

Zhang

, et al. Long COVID among people with HIV: a systematic review and meta-analysis. HIV Med 2024. https://pubmed.ncbi.nlm.nih.gov/39252604/

35.

Kroenke

Spitzer

Williams

JBW

. The PHQ-9 validity of a brief depression severity measure. J Gen Intern Med 2001; 16(9): 606–613.

36.

Spitzer

Kroenke

Williams

JBW

, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166(10): 1092–1097. https://jamanetwork.com/journals/jamainternalmedicine/fullartile/410326

37.

Theou

Pérez-Zepeda

Van Der Valk

, et al. A classification tree to assist with routine scoring of the Clinical Frailty Scale. Age Ageing 2021; 50(4): 1406–1411. https://www.dal.ca/sites/gmr/our-tools/clinical-frailty-scale.html

38.

Klok

Boon

GJAM

Barco

, et al. The Post-COVID-19 Functional Status (PCFS) Scale: a tool to measure functional status over time after COVID-19. Eur Resp J 2020; 56(1). https://publications.ersnet.org/content/erj/early/2020/05/07/13993003.01494-2020

39.

Bohannon

Crouch

. 1-Minute sit-to-stand test: systematic review of procedures, performance, and clinimetric properties. J Cardiopulm Rehabil Prev 2019; 39(1): 2–8. https://journals.lww.com/jcrjournal/fulltext/2019/01000/1_minute_sit_to_stand_test__systematic_review_of.2.aspx

40.

Frailty in older adults - early identification and management - province of British Columbia. https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/frailty#scoringtools

41.

Carfì

Bernabei

Landi

. Persistent symptoms in patients after acute COVID-19. JAMA 2020; 324(6): 603–605. https://pubmed.ncbi.nlm.nih.gov/32644129/

42.

Thaweethai

Jolley

Karlson

, et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA 2023; 329(22): 1934–1946. https://pubmed.ncbi.nlm.nih.gov/37278994/

43.

Davis

Assaf

McCorkell

, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021: 38. https://www.thelancet.com/article/S2589537021002996/fulltext

44.

Trender

Hellyer

Killingley

, et al. Changes in memory and cognition during the SARS-CoV-2 human challenge study. EClinicalMedicine 2024; 76: 102842. https://pubmed.ncbi.nlm.nih.gov/39364271/

45.

Tabacof

Tosto-Mancuso

Wood

, et al. Post-acute COVID-19 syndrome negatively impacts physical function, cognitive function, health-related quality of life, and participation. Am J Phys Med Rehabil 2022; 101(1): 48–52. https://pubmed.ncbi.nlm.nih.gov/34686631/

46.

Cai

Xie

Topol

, et al. Three-year outcomes of post-acute sequelae of COVID-19. Nat Med 2024; 30(6): 1564–1573. https://www.ncbi.nlm.nih.gov/research/coronavirus/

47.

Dong

. Thin-section computed tomography manifestations during convalescence and long-term follow-up of patients with severe acute respiratory syndrome (SARS). Med Sci Monit 2016; 22: 2793–2799. https://pmc.ncbi.nlm.nih.gov/articles/PMC4982531/

48.

Groff

Sun

Ssentongo

, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open 2021; 4(10): e2128568. https://pubmed.ncbi.nlm.nih.gov/34643720/

49.

Cañas

Wolf

Ruddy

, et al. Racial and ethnic disparities post-hospitalization for COVID-19: barriers to access to care for survivors of COVID-19 acute respiratory distress syndrome. Sci Rep 2024; 14(1). https://pubmed.ncbi.nlm.nih.gov/38773184/

50.

Braga

Lepra

Kish

, et al. Neuroinflammation after COVID-19 with persistent depressive and cognitive symptoms. JAMA Psychiatry 2023; 80(8):787. https://pmc.ncbi.nlm.nih.gov/articles/PMC10233457/

51.

Ottaway

Onyango

Kolodin

, et al. “COVID impacted my life in so many ways”: a qualitative study of the lived experiences of the COVID-19 pandemic among people of Black ethnicities living with HIV in England. Ethn Health 2024; 30(2):254–272. https://pubmed.ncbi.nlm.nih.gov/39593273/

52.

Ridge

Broom

Alwan

, et al. Medical ambivalence and Long Covid: the disconnects, entanglements, and productivities shaping ethnic minority experiences in the UK. Soc Sci Med 2024; 366: 117603. https://pubmed.ncbi.nlm.nih.gov/39721163/

53.

Smyth

Ridge

Kingstone

, et al. People from ethnic minorities seeking help for long COVID: a qualitative study. Br J Gen Pract 2024; 74: e814–e822. DOI: 10.3399/BJGP.2023.0631.

54.

Chapman

Durbaba

Tydeman

, et al. Long COVID demographic and secondary care referral characteristics in primary care: analysis of anonymised primary care data from a multiethnic, deprived urban area in the UK. NPJ Prim Care Respir Med 2024; 34(1): 25. https://pubmed.ncbi.nlm.nih.gov/39349473/

55.

Pham

Smith

Card

, et al. Exploring social determinants of health and their impacts on self-reported quality of life in long COVID-19 patients. Sci Rep 2024; 14(1): 30410. https://pubmed.ncbi.nlm.nih.gov/39638836/

56.

Hughes

Haroon

Subramanian

, et al. Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): rasch analysis. BMJ 2022; 377: e070230. https://www.bmj.com/content/377/bmj-2022-070230

57.

Reese

Blau

Casiraghi

, et al. Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes. EBioMedicine 2023; 87: 104413. https://pubmed.ncbi.nlm.nih.gov/36563487/

58.

O’Neil

Madlock-Brown

Wilkins

, et al. Finding Long-COVID: temporal topic modeling of electronic health records from the N3C and RECOVER programs. NPJ Digit Med 2024; 7(1): 296. https://www.nature.com/articles/s41746-024-01286-3

59.

Hipp

Bünning

Munnes

, et al. Problems and pitfalls of retrospective survey questions in COVID-19 studies. Surv Res Methods 2020; 14(2): 109–114. https://ojs.ub.uni-konstanz.de/srm/article/view/7741

60.

Whitaker

Elliott

Bodinier

, et al. Variant-specific symptoms of COVID-19 in a study of 1,542,510 adults in England. Nat Commun 2022; 13(1): 6856–6910. https://www.nature.com/articles/s41467-022-34244-2

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.20 MB